Effect of low-close tumor necrosis factor-α in combination with STEALTH® liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 743-750

  Hoving, Saske ^a   Van Tiel, Sandra T ^a   Eggermont, Alexander M M ^a   Ten Hagen, Timo L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cisplatin; Rat sarcoma; SPI 077; STEALTH liposomes; Systemic treatment; TNF

Indexed keywords

CISPLATIN; DOXORUBICIN; LIPOSOME; STEALTH LIPOSOMAL CISPLATIN; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN; SPI 77, LIPOSOMAL; SPI-77, LIPOSOMAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; GROWTH INHIBITION; LIVER TOXICITY; LOW DRUG DOSE; MALE; NEPHROTOXICITY; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RAT; SOFT TISSUE SARCOMA; TOXICITY TESTING; ANIMAL; BONE TUMOR; BROWN NORWAY RAT; DOSE RESPONSE; HUMAN; SOFT TISSUE TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIPOSOMES; MALE; OSTEOSARCOMA; RATS; RATS, INBRED BN; RECOMBINANT PROTEINS; SOFT TISSUE NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17444417500     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bandak S, Goren D, Horowitz A et al: Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs 10: 911-920, 1999.
2. Eroglu A, Kocaoglu H, Demirci S et al: Isolated limb perfusion with cisplatin and doxorubicin for locally advanced soft tissue sarcoma of an extremity. Eur J Surg Oncol 26: 213-221, 2000.
3. Gondal JA, Preuss HG, Swartz R et al: Comparative pharmacological, toxicological and antitumoral evaluation of free and liposome-encapsulated cisplatin in rodents. Eur J Cancer 29A: 1536-1542, 1993.
4. Iga K, Hamaguchi N, Igari Y et al: Increased tumor cisplatin levels in heated tumors in mice after administration of thermosensitive, large unilamellar vesicles encapsulating cisplatin. J Pharm Sci 80: 522-525, 1991.
5. Newman MS, Colbern GT, Working PK et al: Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43: 1-7, 1999.
6. Thamm DH and Vail DM: Preclinical evaluation of a sterically stabilized liposome-encapsulated cisplatin in clinically normal cats. Am J Vet Res 59: 286-289, 1998.
7. Veal GJ, Griffin MJ, Price E et al: A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. Br J Cancer 84: 1029-1035, 2001.
8. Meerum TJ, Groenewegen G, Pluim D et al: Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol 49: 201-210, 2002.
9. Burger KN, Staffhorst RW, de Vijlder HC et al: Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat Med 8: 81-84, 2002.
10. Allen TM, Newman, MS, Woodle MC et al: Pharmacokinetics and antitumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer 62: 199-204, 1995.
11. Lasic DD: Doxorubicin in sterically stabilized liposomes. Nature 380: 561-562, 1996.
12. Papahadjopoulos D, Allen TM, Gabizon A et al: Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88: 11460-11464, 1991.
13. Sparano JA and Winer EP: Liposomal anthracyclines for breast cancer. Semin Oncol 28: 32-40, 2001.
14. van Der Veen AH, Eggermont AM, Seynhaeve AL et al: Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats. Int J Cancer 77: 901-906, 1998.
15. Gabizon A and Martin F: Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54 Suppl 4: 15-21, 1997.
16. Wu NZ, Da D, Rudoll TL et al: Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res 53: 3765-70, 1993.
17. Harrington KJ, Rowlinson-Busza G, Syrigos KN et al: Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res 6: 4939-4949, 2000.
18. Vaage J, Donovan D, Wipff E et al: Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int J Cancer 80: 134-137, 1999.
19. Harrington KJ, Lewanski CR, Northcote AD et al: Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 12: 493-496, 2001.
20. Kim ES, Lu C, Khuri FR et al: A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 34: 427-432, 2001.
21. van Der Veen AH, de Wilt JH, Eggermont AM et al: TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 82: 973-980, 2000.
22. ten Hagen TL, van Der Veen AH, Nooijen PT et al: Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer 87: 829-37, 2000.
23. Brouckaert P, Takahashi N, van Tiel ST et al: Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. Int J Cancer 109: 442-448, 2004.
24. Manusama ER, Nooijen PT, Stavast J et al: Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg 83: 551-555, 1996.
25. Skehan P, Storeng R, Scudiero D et al: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
26. DeConti RC, Toftness BR, Lange RC et al: Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 33: 1310-1315, 1973.
27. Evans WE, Yee GC, Crom WR et al: Clinical pharmacology of bleomycin and cisplatin. Head Neck Surg 4: 98-110, 1981.
28. Chan KK, Cohen JL, Gross JF et al: Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model. Cancer Treat Rep 62: 1161-1171, 1978.
29. Robert J, Bui NB and Vrignaud P: Pharmacokinetics of doxorubicin in sarcoma patients. Eur J Clin Pharmacol 31: 695-699, 1987.
30. Robert J, Illiadis A, Hoerni B et al: Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. Eur J Cancer Clin Oncol 18: 739-745, 1982.
31. Burger KN, Staffhorst RW and de Kruijff B: Interaction of the anti-cancer drug cisplatin with phosphatidylserine in intact and semi-intact cells. Biochim Biophys Acta 1419: 43-54, 1999.
32. Zamboni WC, Gervais AC, Egorin MJ et al: Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 53: 329-336, 2004.
33. Brett J, Gerlach H, Nawroth P et al: Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med 169: 1977-1991, 1989.
34. Partridge CA, Horvath CJ, Del Vecchio PJ et al: Influence of extracellular matrix in tumor necrosis factor-induced increase in endothelial permeability. Am J Physiol 263: L627-L633, 1992.
35. de Wilt JH, ten Hagen TL, de Boeck G et al: Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82: 1000-1003, 2000.